Vieworks Wins FDA Approval for Its Newest VIVIX-S F series

Vieworks Wins FDA Approval for Its Newest VIVIX-S F series

ANYANG, South Korea, Aug. 5, 2022 /PRNewswire/ — Vieworks, a leading digital X-ray imaging solution provider based in South Korea, noted that its newest VIVIX-S F series has been authorized by the US Food and Drug Administration (FDA) last July. Regulatory clearance from the FDA will allow Vieworks to commercialize its new VIVIX-S F series, which is Vieworks’ premium static X-ray DR flat panel detectors equipped with advanced technology and cutting-edge hardware design. The cassette-sized DR detectors are offered in 3 sizes – 25x30cm (VIVIX-S 2530FW), 36x43cm (VIVIX-S 3643FW), and 43x43cm (VIVIX-S 4343FW).


VIVIX-S F series

1. FINEST Image Quality

High resolution images with 99µm pixel pitch Semi-dynamic feature (multi-frame mode) Anatomy-based image enhancement with photon-understanding AI solution Advanced image processing technology (VXvue, Software-based Scatter Correction)

2. FINEST Durability

Unbreakable glass-free TFT (flexible TFT) Excellent durability (1.5m drop tested, 400kg load limit) IP67 water and dust resistance Wider operating temperature

3. FINEST Usability

Lighter weight for greater portability Convenient charging (wireless charging, separate battery charger, USB-C type, magnetic tether, cradle) Long lasting battery life (16 hours with two batteries, hot-swap mode) Easy usage with user-friendly functions (Fast and convenient detector sharing by NFC, OLED status screen)

Share on linkedin
Share on facebook
Share on twitter
Share on print
Share on email
Share on linkedin
Share on facebook
Share on twitter
Share on print
Share on email

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Generated by Feedzy
MEDICA 2022 banner

Where healthcare is going.
MEDICA 2022 – Top in all medical areas

We are at Hall 17 / A07

tradewinds booth location at MEDICA 2022

TradeWinds Consulting

Are you in?

Subscribe to receive exclusive content and notifications to your inbox